Breaking News

There were more mergers and acquisitions in the omics space in 2018, reversing the decline experienced in 2017.

Blockchain-based startup EncrypGen will take advantage of Murrieta Genomics' sequencing lab and business services to market its Gene-Chain platform for data sharing.

The study authors cautioned that immunological signatures cannot be predicted from tumor mutational burden or microenvironment analysis of a single biopsy alone.

The partners will leverage Singapore’s clinical network to collect a variety of 'omics data from consenting individuals and store the data for local researchers to investigate.  

The assay is designed to quantitate HBV DNA in serum or plasma to assist in the treatment of chronic HBV-infected patients receiving antiviral therapy.

Evogene and Tropical Melhoramento & Genetica aim to develop non-genetically-modified nematode-resistant soybeans using CRISPR genome editing.

Biocept will offer patient data from its liquid biopsy tests to Prognos, who will apply artificial intelligence to ensure that patients receive correct therapies. 

The firm noted that it has already borrowed $350 million under the revolving credit facility. The funds may be used for general corporate and other purposes.

The researchers will not only explore tissue and circulating biomarkers but also the role of the microbiome in predicting benefit from immune checkpoint inhibitors.

The company said it will use the award to further develop its ImmuneProfiler neoantigen prediction technology for personalized cancer medicine.

Researchers found 253 candidate disease genes, based on 10,927 exomes from patients with autism spectrum disorder, developmental delay, or intellectual disability.

The firms will jointly invest in establishing a joint venture company in China, and Autobio has also invested €10 million in Mobidiag.

Last week, GenomeWeb's readers were most interested in 10x Genomics' acquisition of Spatial Transcriptomics.

The company will continue to explore strategic alternatives with financial advisor Raymond James & Associates.

H3, a subsidiary of Japanese drugmaker Eisai, is developing personalized cancer treatments targeting genomic alterations, including aberrant RNA splicing.

The researchers suggested that the regions they found should be included in diagnostic assays for unexplained cases of disorders of sex development.

A multi-omic analysis implicated a handful of transcription factors, along with genes and regulatory RNAs down- and upstream of them, in metastatic colorectal cancer.

A systematic analysis of CRISPR genome editing at nearly 1,500 target sites has yielded some patterns that could make genome editing more precise.

The partners will identify patients with gastrointestinal or endometrial cancers who may benefit from immune checkpoint inhibitor therapy using Biotype's technology.

Researchers have identified promising polygenic risk scores for estimating overall breast cancer risk as well as estrogen receptor-positive forms of disease.

Shivom and Lifebit will offer an artificial intelligence-based platform for identifying the right patients for enrollment in clinical trials.

The researchers generated a skull shape score and applied it to a European ancestry cohort to tease out introgressed Neanderthal DNA linked to head shape.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.